Home Pharma China Web Edition Pharma China Archives Online Databases Info/Download/Order Business Services Service Provider Directory About Us
Location:Home > Pharma China Web Edition
 
 
 
 
 
Expert Opinions
 
Uptake of Novel Therapies in China and the Impact of Geography, Insurance and Patient Income Levels
 
6/29/2010

By Pieter De Richter, Synovate Healthcare

While drugs in novel therapeutic classes often show a dramatic uptake in Western countries – even when priced significantly above existing classes – these products tend to take much longer to have an impact in China, and their peak shares are often much lower than in the US and EU, or even other APAC countries. The chart below (Figure 1) illustrates this reality, using the uptake of monoclonal antibodies for drug-treated cancer patients as two example of this discrepancy. This data was taken from Synovate Healthcare’s China Oncology Monitor, based on a sample of over 500 cancer-treating physicians per wave, and a patient sample of over 11,000 drug-treated cancer patients per year from tier I and II cities; the Australian data, included for comparison, is based on Synovate Healthcare’s Australia Oncology Monitor.

This article contains graphics that can not be shown properly on this website, please download the PDF by clicling on the following link:

Uptake of novel therapies in China and the impact of geography.pdf

 
 
Relate Articles